This case-based online mentor workshop podcast focuses on practical strategies to manage metastatic breast cancer in your patients with HER2-positive disease. Presented by Reshma Mahtani, DO, it includes prerecorded Q & A from the proceedings of live audioconferences. This workshop podcast is a sequ…
Dr. Mahtani answers additional questions from the live audience including how protocols have evolved in recent years and the need for accurate HER2 testing.
Dr. Mahtani provides take-away messages from her case presentation on HER2-positive breast cancer, and then answers questions from the live audience. Topics include the use of trastuzumab and novel therapies in development for HER2-positive metastatic breast cancer.
Dr. Mahtani discusses the use of trastuzumab in patients with HER2-positive metastatic breast cancer after progression on first-line trastuzumab.
Dr. Mahtani discusses toxicity associated with combination regimens that include capecitabine and lapatinib.
Dr. Mahtani reviews the incidence of and factors associated with brain metastases in patients with HER2-positive metastatic breast cancer.
Dr. Mahtani highlights the importance of novel therapies, such as TDM-1, in the treatment of HER2-positive metastatic breast cancer.
Dr. Mahtani discusses the role of trastuzumab in selected patients with small HER2-positive tumors.
Dr. Mahtani presents the case of a 44-year-old woman with a small HER2-positive tumor who progressed 2 years after initial mastectomy.